Mavis C - Search Results

1

Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.

Frys S, Simons Z, Hu Q, Barth MJ, Gu JJ, Mavis C, Skitzki J, Song L, Czuczman MS, Hernandez-Ilizaliturri FJ. Frys S, et al. Among authors: mavis c. Br J Haematol. 2015 May;169(4):506-19. doi: 10.1111/bjh.13318. Epub 2015 Feb 23. Br J Haematol. 2015. PMID: 25712263 Free PMC article.

2

Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells.

Olejniczak SH, Blickwedehl J, Belicha-Villanueva A, Bangia N, Riaz W, Mavis C, Clements JL, Gibbs J, Hernandez-Ilizaliturri FJ, Czuczman MS. Olejniczak SH, et al. Among authors: mavis c. Blood. 2010 Dec 16;116(25):5605-14. doi: 10.1182/blood-2009-12-259754. Epub 2010 Oct 7. Blood. 2010. PMID: 20930068 Free PMC article.

3

Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.

Brem EA, Thudium K, Khubchandani S, Tsai PC, Olejniczak SH, Bhat S, Riaz W, Gu J, Iqbal A, Campagna R, Knight J, Mavis C, Hoskin P, Deeb G, Gibbs JF, Fetterly G, Czuczman MS, Hernandez-Ilizaliturri FJ. Brem EA, et al. Among authors: mavis c. Br J Haematol. 2011 Jun;153(5):599-611. doi: 10.1111/j.1365-2141.2011.08669.x. Epub 2011 Apr 15. Br J Haematol. 2011. PMID: 21492126 Free PMC article.

4

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.

Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS. Barth MJ, et al. Among authors: mavis c. Br J Haematol. 2012 Feb;156(4):490-8. doi: 10.1111/j.1365-2141.2011.08966.x. Epub 2011 Dec 9. Br J Haematol. 2012. PMID: 22150234 Free article.

5

MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.

Wenzel SS, Grau M, Mavis C, Hailfinger S, Wolf A, Madle H, Deeb G, Dörken B, Thome M, Lenz P, Dirnhofer S, Hernandez-Ilizaliturri FJ, Tzankov A, Lenz G. Wenzel SS, et al. Among authors: mavis c. Leukemia. 2013 Jun;27(6):1381-90. doi: 10.1038/leu.2012.367. Epub 2012 Dec 21. Leukemia. 2013. PMID: 23257783

6

The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.

Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, Czuczman NM, Mavis C, Skitzki JJ, Czuczman MS. Gu JJ, et al. Among authors: mavis c. Br J Haematol. 2013 Sep;162(5):657-69. doi: 10.1111/bjh.12452. Epub 2013 Jul 4. Br J Haematol. 2013. PMID: 23826755 Free PMC article.

7

MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.

Gu JJ, Hernandez-Ilizaliturri FJ, Mavis C, Czuczman NM, Deeb G, Gibbs J, Skitzki JJ, Patil R, Czuczman MS. Gu JJ, et al. Among authors: mavis c. Anticancer Drugs. 2013 Nov;24(10):1030-8. doi: 10.1097/CAD.0000000000000008. Anticancer Drugs. 2013. PMID: 23995855 Free PMC article.

8

Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.

Barth MJ, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ. Barth MJ, et al. Among authors: mavis c. Clin Cancer Res. 2015 Oct 1;21(19):4391-7. doi: 10.1158/1078-0432.CCR-15-0056. Epub 2015 May 11. Clin Cancer Res. 2015. PMID: 25964296 Free PMC article.

9

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.

Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y. Xue K, et al. Among authors: mavis c. J Cancer Res Clin Oncol. 2016 Feb;142(2):379-87. doi: 10.1007/s00432-015-2026-y. Epub 2015 Aug 28. J Cancer Res Clin Oncol. 2016. PMID: 26314218

10

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.

Czuczman NM, Barth MJ, Gu J, Neppalli V, Mavis C, Frys SE, Hu Q, Liu S, Klener P, Vockova P, Czuczman MS, Hernandez-Ilizaliturri FJ. Czuczman NM, et al. Among authors: mavis c. Blood. 2016 Mar 3;127(9):1128-37. doi: 10.1182/blood-2015-04-640920. Epub 2015 Dec 16. Blood. 2016. PMID: 26675347 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

29 results

Search Page